A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children age 7 years through 18 years

Registry ID

EUCTR2014-003400-70

Source registry

EUCTR

Phase

PHASE3

Sponsor

AstraZeneca K.K.

Last update

2026-08-16

Conditions

• Healthy Children

Summary

To assess the efficacy (the incidence of laboratory-confirmed influenza infection caused by any community-acquired wild-type strains matched to the vaccine) of MEDI3250 compared to placebo. To assess the safety and tolerability of MEDI3250 compared to placebo.

Related clinical trials

• Prevention With Ismigen of RTIs in Kids
• Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
• To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Allergy and Immune Function in Infants
• Outdoor Science Education and Child Well-being in Primary Schools: Protocol for a Cluster Randomized Controlled Trial on Learning, Connection to Nature, Eco-anxiety, and Stress
• Functional Training and Dynamic Play Exercise on Gross Motor Skills, Physical Fitness, and Balance in Healthy Children
• Symptoms, Pulmonary Function, Muscle Strength, Exercise Capacity, and Frailty in Esophageal Atresia vs. Healthy Peers

View on source registry